Latest BioDelivery Sciences Stories
2014 - A Year of Many Significant Milestones, with More Expected for 2015, as BDSI Continues its Growth as an Integrated Specialty Pharmaceutical Company RALEIGH, N.C., March 16, 2015 /PRNewswire/
Transaction provides BDSI the opportunity to seek a new partner for ONSOLIS in the U.S., Canada and Mexico RALEIGH, N.C., Jan.
Website and Mobile App Offer Comprehensive Array of Information and Resources to Support Patients and Their Families RALEIGH, N.C., Dec.
BUNAVAIL(TM) (buprenorphine and naloxone) buccal film now available by prescription for the maintenance treatment of opioid dependence RALEIGH, N.C., Nov.
BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) approved by FDA for the maintenance treatment of opioid dependence; US launch planned for late Q3 RALEIGH, N.C., Aug.
BUNAVAIL PDUFA date June 7, 2014; Pre-launch activities underway to support an anticipated late Q3 2014 launch RALEIGH, N.C., May 8, 2014 /PRNewswire/ -- BioDelivery Sciences International,
BEMA Buprenorphine Phase 3 opioid naive study database lock imminent; triggers $10M milestone payment from Endo Pharmaceuticals RALEIGH, N.C., Jan.
- a slit in a tire to drain away surface water and improve traction.